Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07514858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

Study acronym: DARE2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary and study completion moved earlier from Dec 30, 2028 to Oct 3, 2028 · Study sites: 0 to 2 · Start date changed from estimate of Jun 30, 2026 to Jul 28, 2026v2 Show 3 more changesShow less
    • Primary and study completion moved earlier from Dec 30, 2028 to Oct 3, 2028
    • Study sites: 0 to 2
    • Start date changed from estimate of Jun 30, 2026 to Jul 28, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, but still experience periods of time when their medication does not adequately control their motor symptoms. Some may also experience dyskinesia (other type of involuntary movements) as a side effect of their PD medications. The main goal of the trial is to learn whether adding Lu AF28996 to participants' optimized PD medications will help extending the time they spend with their movement symptoms being well-controlled and without bothersome dyskinesia.
Trial Details
NCT Number NCT07514858
Lead Sponsor H. Lundbeck A/S
Conditions Parkinson's Disease
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov